Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $108.50 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:10 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

merck kgaa (MKGAF) Snapshot

Open
$108.50
Previous Close
$108.50
Day High
$108.50
Day Low
$108.50
52 Week High
04/8/15 - $117.55
52 Week Low
05/13/14 - $85.00
Market Cap
48.8B
Average Volume 10 Days
105.9
EPS TTM
--
Shares Outstanding
129.2M
EX-Date
04/20/15
P/E TM
--
Dividend
$0.97
Dividend Yield
0.97%
Current Stock Chart for MERCK KGAA (MKGAF)

Related News

No related news articles were found.

merck kgaa (MKGAF) Related Businessweek News

No Related Businessweek News Found

merck kgaa (MKGAF) Details

Merck Kommanditgesellschaft auf Aktien discovers, develops, manufactures, and markets pharmaceutical and chemical products worldwide. The company provides pharmaceutical and biological prescription drugs to treat cancer, multiple sclerosis, infertility, growth disorders, and cardiovascular and metabolic diseases; fertility drugs for every stage of the reproductive cycle; hypoallergenic products for specific immunotherapy and diagnosis of type 1 allergies; and biosimilars focusing on oncology and inflammatory disorders. It also manufactures and markets over-the-counter pharmaceuticals to address mobility, women’s and children’s health, cough and cold, and everyday health protection under the Neurobion, Bion, Seven Seas, Nasivin, Femibion, Dolo-Neurobion, Floratil, Sangobion, Vigantoletten, Apaisyl, and Kytta brand names. In addition, the company offers life science tools and technologies for use in the research, development, and manufacture of biotechnological and pharmaceutical drug therapies, as well as in research and application laboratories. Further, it provides specialty chemicals that are used in various end products, including liquid crystals for displays; LED materials for lighting, as well as organic light-emitting diode materials for lighting and displays; functional materials for solar panels and energy solutions; effect pigments, as well as active ingredients and fillers for cosmetics, food, and pharmaceutical products; pigments and functional materials for coatings, printing, and plastics; and specialty chemical materials for the electronics industry. The company has a strategic alliance with Pfizer Inc. to develop and commercialize active ingredients in immuno-oncology; and strategic immuno-oncology collaboration with MorphoSys to discover and develop therapeutic antibodies against immune checkpoints. Merck Kommanditgesellschaft auf Aktien was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA is a subsidiary of E. Merck KG.

39,639 Employees
Last Reported Date: 03/3/15
Founded in 1668

merck kgaa (MKGAF) Top Compensated Officers

Chairman of Executive Board and Chief Executi...
Total Annual Compensation: €6.6M
Group Chief Financial Officer and Member of E...
Total Annual Compensation: €1.2M
Chief Executive Officer of Life Science & Per...
Total Annual Compensation: €4.7M
Vice Chairman of Executive Board and Deputy C...
Total Annual Compensation: €6.0M
Head of Group Human Resources, General Partne...
Total Annual Compensation: €4.0M
Compensation as of Fiscal Year 2014.

merck kgaa (MKGAF) Key Developments

Merck Millipore Introduces Magna ChIRP RNA Interactome Kits

Merck Millipore introduced Magna ChIRP RNA Interactome Kits, which allow researchers to more easily identify, recover and analyze regions of chromatin that interact with chromatin-associated RNAs such as long non-coding RNA (lncRNA). The highly effective multiprobe-based capture strategy uses cross-linked chromatin to provide reliable detection and discovery of RNA-associated genomic DNA sequences, RNA sequences and proteins. The new kits use the ChIRP method (Chromatin Isolation by RNA Purification) to isolate chromatin complexes using RNA as the target, allowing researchers to pinpoint specific sites of genomic interaction for chromatin-associated RNAs. The kits simplify the ChIRP method, providing all necessary buffers, enzymes and reagents in one validated kit, as well as a negative control probe set and detailed protocol with capture probe design guidelines. In addition, first-time users can opt for the EZ-Magna ChIRP kit, which includes a positive control capture probe set and detection primers that make it easier to validate an experiment's success.

Merck KGaA, Darmstadt, and Pfizer Inc Announce Initiation and First Patient Treatment in the International Phase III Study to Assess Efficacy and Safety of Investigational Cancer Immunotherapy Avelumab

Merck KGaA, Darmstadt, and Pfizer Inc. announced the initiation and first patient treated in the international Phase III study (EMR 100070-004) designed to assess the efficacy and safety of the investigational cancer immunotherapy avelumab (MSB0010718C), compared with docetaxel, in patients with stage IIIb/IV non-small cell lung cancer (NSCLC) who have experienced disease progression after receiving a prior platinum-containing doublet therapy. The Phase III study is an open-label, multicenter, 1:1 randomized clinical trial where patients with stage IIIb/IV NSCLC will receive either avelumab or docetaxel, regardless of PD-L1 status. Approximately 650 patients will participate across 290 sites in more than 30 countries in North America, South America, Asia, Africa and Europe. In North America, clinical trials on behalf of Merck KGaA, Darmstadt, Germany, will be conducted by EMD Serono, the company’s US and Canadian biopharmaceutical businesses. The study is part of the JAVELIN clinical trial program for avelumab. The primary endpoint of the study is overall survival (OS) in patients with programmed death-ligand 1 positive (PD-L1+) stage IIIb/IV NSCLC who have experienced disease progression after receiving a prior platinum-containing doublet therapy. Secondary endpoints will be assessed across the entire study population regardless of PD-L1 status and include OS; overall response rate (ORR); progression-free survival (PFS); and patient-reported outcomes. The JAVELIN clinical trial program also includes an international Phase II trial to investigate avelumab in patients with metastatic Merkel cell carcinoma; an international Phase I trial to investigate avelumab in patients with metastatic or locally advanced solid tumors, and a Phase I trial to investigate avelumab in Japanese patients with metastatic or locally advanced solid tumors with an expansion part in Asian patients with gastric cancer. The Phase I program for avelumab includes more than 840 patients treated across multiple tumor types, including NSCLC, breast cancer, gastric cancer, ovarian cancer, bladder cancer, melanoma and mesothelioma.

Merck KGaA Confirms Earnings Guidance for the Full Year of Fiscal 2015

Merck KGaA confirmed earnings guidance for the full year of fiscal 2015. For the year, the company confirmed its cautiously optimistic full-year guidance for slight sales growth and stable or slightly higher core earnings in 2015. However, if the USD 17 billion (EUR 15.7 billion) purchase of US life science company Sigma-Aldrich Corp. is completed by mid-2015 as planned, growth will be higher. In this case, net sales should grow at a double-digit percentage rate, while earnings before interest, tax, depreciation and amortization (EBITDA) are expected to increase sharply.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MKGAF:US $108.50 USD 0.00

MKGAF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akzo Nobel NV €69.06 EUR +0.64
Johnson Matthey PLC 3,330 GBp +12.00
Koninklijke DSM NV €50.96 EUR -1.09
Solvay SA €136.25 EUR +1.60
Yara International ASA 393.10 NOK -1.50
View Industry Companies
 

Industry Analysis

MKGAF

Industry Average

Valuation MKGAF Industry Range
Price/Earnings 33.7x
Price/Sales 3.4x
Price/Book 3.3x
Price/Cash Flow 10.0x
TEV/Sales 0.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERCK KGAA, please visit www.merck.de. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.